Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8BDL

VCB in complex with compound 27

Summary for 8BDL
Entry DOI10.2210/pdb8bdl/pdb
DescriptorElongin-B, Elongin-C, von Hippel-Lindau disease tumor suppressor, ... (5 entities in total)
Functional Keywordsprotac, degrader, complex, e3 ligase, vhl, vcb, ligase, vh032
Biological sourceHomo sapiens (human)
More
Total number of polymer chains12
Total formula weight168399.98
Authors
Sorrell, F.J.,Mueller, J.E.,Lehmann, M.,Wegener, A. (deposition date: 2022-10-19, release date: 2023-02-15, Last modification date: 2024-10-16)
Primary citationKrieger, J.,Sorrell, F.J.,Wegener, A.A.,Leuthner, B.,Machrouhi-Porcher, F.,Hecht, M.,Leibrock, E.M.,Muller, J.E.,Eisert, J.,Hartung, I.V.,Schlesiger, S.
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.
Chemmedchem, 18:e202200615-e202200615, 2023
Cited by
PubMed Abstract: Herein, we describe a systematic SAR- and SPR-investigation of the peptidomimetic hydroxy-proline based VHL-ligand VH032, from which most to-date published VHL-targeting PROTACs have been derived. This study provides for the first time a consistent data set which allows for direct comparison of structural variations including those which were so far hidden in patent literature. The gained knowledge about improved VHL binders was used to design a small library of highly potent BRD4-degraders comprising different VHL exit vectors. Newly designed degraders showed favorable molecular properties and significantly improved degradation potency compared to MZ1.
PubMed: 36749883
DOI: 10.1002/cmdc.202200615
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.295 Å)
Structure validation

227344

數據於2024-11-13公開中

PDB statisticsPDBj update infoContact PDBjnumon